{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:53:27Z","timestamp":1780617207424,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010355","name":"Hellenic Society of Medical Oncology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010355","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone &amp; IGF Research"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ghir.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T19:03:40Z","timestamp":1487271820000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4975-9942","authenticated-orcid":false,"given":"Georgios Z.","family":"Papadakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Souglakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios K.","family":"Alegakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Samonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulas","family":"Bagci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Makrigiannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odysseas","family":"Zoras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2017.02.001_bb0005","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ghir.2017.02.001_bb0010","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/annonc\/mdv001","article-title":"European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?","volume":"26","author":"Malvezzi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","article-title":"Systemic spread is an early step in breast cancer","volume":"13","author":"H\u00fcsemann","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ghir.2017.02.001_bb0020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.breast.2014.07.002","article-title":"The significance of circulating tumour cells in breast cancer: a review","volume":"23","author":"Castle","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.ghir.2017.02.001_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1470-2045(04)01381-6","article-title":"Circulating tumor cells in breast cancer","volume":"5","author":"Ring","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2015.06.020","article-title":"Circulating tumor cells in early breast cancer: a connection with vascular invasion","volume":"367","author":"Maltoni","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ghir.2017.02.001_bb0035","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-14-1190","article-title":"Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility","volume":"21","author":"Ignatiadis","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ghir.2017.02.001_bb0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2017.02.001_bb0045","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2907","article-title":"Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment","volume":"13","author":"Giuliano","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ghir.2017.02.001_bb0050","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdr263","article-title":"High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients","volume":"23","author":"Pierga","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0060","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","article-title":"Circulating tumour cells in non-metastatic breast cancer: a prospective study","volume":"13","author":"Lucci","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/annonc\/mdp391","article-title":"Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer","volume":"21","author":"Bidard","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0070","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1200\/JCO.2007.11.7762","article-title":"Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer","volume":"25","author":"Ignatiadis","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0075","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.2008.18.0497","article-title":"Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer","volume":"27","author":"Xenidis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clbc.2014.04.001","volume":"14","author":"Tryfonidis","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0085","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-12-1587","article-title":"Meta-analysis of the prognostic value of circulating tumor cells in breast cancer","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ghir.2017.02.001_bb0090","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/er.2006-0001","article-title":"The role of the IGFsystem in cancer growth and metastasis: overview and recent insights","volume":"28","author":"Samani","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2017.02.001_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J","article-title":"Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis","volume":"183","author":"Grimberg","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1470-2045(02)00731-3","article-title":"Insulin-like growth factors and cancer","volume":"3","author":"Furstenberger","year":"2002","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0110","first-page":"761","article-title":"The insulin-like growth factor-binding protein (IGFBP) superfamily","volume":"20","author":"Hwa","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2017.02.001_bb0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/plac.1999.0498","article-title":"Spatial and temporal patterns of expression of messenger RNA for insulin-like growth factors and their binding proteins in the placenta of man and laboratory animals","volume":"21","author":"Han","year":"2000","journal-title":"Placenta"},{"key":"10.1016\/j.ghir.2017.02.001_bb0120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2015.06.003","article-title":"Insulin-like growth factor binding-protein-3 (IGFBP-3)","volume":"29","author":"Ranke","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.02.001_bb0125","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0140-6736(04)16044-3","article-title":"Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis","volume":"363","author":"Renehan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ghir.2017.02.001_bb0130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ijc.20233","article-title":"IGF-I and breast cancer: a metaanalysis","volume":"111","author":"Shi","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ijc.20253","article-title":"Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausalbreast cancer: a meta-analysis of literature","volume":"111","author":"Sugumar","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0140","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ijc.20975","article-title":"IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses","volume":"115","author":"Renehan","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1055-9965.EPI-04-0561","article-title":"Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk","volume":"14","author":"Schernhammer","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ghir.2017.02.001_bb0150","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1677\/erc.1.01150","article-title":"IGF-I, IGFBP-3 and breast cancer risk in women: the European prospective investigation into cancer and nutrition (EPIC)","volume":"13","author":"Rinaldi","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0155","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1470-2045(10)70095-4","article-title":"Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies","volume":"11","author":"Key","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0160","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/ijc.28589","article-title":"Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status-a prospective study within the EPIC cohort","volume":"134","author":"Kaaks","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0165","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.ejca.2007.05.021","article-title":"The insulin-like growth factor 1 receptor in cancer: old focus, new future","volume":"43","author":"Hartog","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0170","doi-asserted-by":"crossref","first-page":"56836","DOI":"10.1371\/journal.pone.0056836","article-title":"Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients","volume":"8","author":"Pizon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ghir.2017.02.001_bb0175","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2007.13.6523","article-title":"Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse","volume":"26","author":"Pachmann","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0180","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ijc.27753","article-title":"Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer","volume":"132","author":"Duggan","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2002.20.1.42","article-title":"Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study","volume":"20","author":"Goodwin","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0190","first-page":"235","article-title":"IGF1 and risk of additional breast cancer in the WHEL study","volume":"18","author":"Al-Delaimy","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0195","doi-asserted-by":"crossref","first-page":"17191722","DOI":"10.1158\/1055-9965.EPI-07-0654","article-title":"Serum insulin like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis","volume":"17","author":"Pasanisi","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ghir.2017.02.001_bb0200","first-page":"1610","article-title":"Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion","volume":"76","author":"Blum","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl. 2","key":"10.1016\/j.ghir.2017.02.001_bb0205","first-page":"73","article-title":"Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency","volume":"55","author":"Clemmons","year":"2001","journal-title":"Horm. Res."},{"key":"10.1016\/j.ghir.2017.02.001_bb0210","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.02.001_bb0215","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0959-8049(97)00014-2","article-title":"The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19","volume":"33","author":"Schoenfeld","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0220","first-page":"5145","article-title":"Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system","volume":"9","author":"Stathopoulou","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ghir.2017.02.001_bb0225","series-title":"Breast Cancer","first-page":"9","article-title":"Epithelial-To-Mesenchymal Transition in Breast Cancer: A Role for Insulin-like Growth Factor I and Insulin-like Growth Factor-Binding Protein 3?","volume":"Vol. 7","author":"Zielinska","year":"2015"},{"key":"10.1016\/j.ghir.2017.02.001_bb0230","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1186\/1471-2407-14-651","article-title":"Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer","volume":"14","author":"Papadaki","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ghir.2017.02.001_bb0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10434-001-0025-5","article-title":"Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesions","volume":"8","author":"Holdaway","year":"2001","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ghir.2017.02.001_bb0240","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.breast.2013.07.038","article-title":"Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer","volume":"22","author":"Hartog","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ghir.2017.02.001_bb0245","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10549-013-2452-y","article-title":"Plasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women","volume":"138","author":"Llanos","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ghir.2017.02.001_bb0250","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1530\/eje.0.1360608","article-title":"Effect of natural menopause on serum levels of IGF-I and IGF-binding proteins: relationship with bone mineral density and lipid metabolism in perimenopausal women","volume":"136","author":"Nasu","year":"1997","journal-title":"Eur. J. Endocrinol."},{"issue":"Suppl. 1","key":"10.1016\/j.ghir.2017.02.001_bb0255","first-page":"8","article-title":"Insulin-like growth factor I levels in healthy adults","volume":"62","author":"Landin-Wilhelmsen","year":"2004","journal-title":"Horm. Res."}],"container-title":["Growth Hormone &amp; IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:50:04Z","timestamp":1761087004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637417300084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":51,"alternative-id":["S1096637417300084"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2017.02.001","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}